Introduction
============

*Mycobacterium tuberculosis* is a pathogenic bacterium that causes the infectious disease tuberculosis. Estimates indicate that approximately one-third of the world\'s population is infected with *M. tuberculosis* and approximately 1.8 million deaths were attributable to tuberculosis in 2008 (WHO, 2010)[^1^](#fn1){ref-type="fn"}. Survival of *M. tuberculosis* following its uptake by alveolar macrophages and subsequent replication and multiplication in the hostile environment is a challenging task to the pathogen (Smith, [@B34]; Tischler and McKinney, [@B37]). Within the hostile macrophage environment *M. tuberculosis* is believed to face reactive oxygen and nitrogen species (ROS, RNS), acidic pH of phagolysosome compartments and possibly antimicrobial peptides. ROS and RNS damage DNA, lipids, and proteins and thereby promote pathogen killing. *Mycobacterium tuberculosis* multiplies in this hostile environment by efficiently operating multiple stress resistance pathways (reviewed in (Smith, [@B34]; Tischler and McKinney, [@B37]). One of these elegant strategies includes the operation of proteasome machinery for processing RNS damaged proteins (Darwin et al., [@B5]). This pathway includes the activities of proteasomal core subunit PrcBA, accessory factors Mpa and PafA that recognize specific proteins for targeted degradation by the activity of prokaryotic ubiquitin-like protein, Pup.

It is expected that the net charge or membrane potential of the bacterial cell wall is determined by its composition, including the ratio of acidic to basic phospholipids. Thus, another survival strategy involves the modulation of membrane surface charge so that the pathogen can weather the action of host cationic antimicrobial peptides (CAMPs; Peschel, [@B25]; Kraus and Peschel, [@B17]). Gram positive pathogens, such as *Staphylococcus aureus*, decrease net membrane charge by adding lysine groups on acidic phospholipid phosphatidylglycerol (PG) and thereby resist the action of CAMPs (Peschel et al., [@B26]). It is also known that other acidic phospholipids, such as cardiolipin (CL), are subject to such modification (Thedieck et al., [@B36]). We recently showed that a two-domain lysyltransferase and lysyl-tRNA-synthetase protein encoded by *lys*X gene of *M. tuberculosis* is necessary for PG lysinylation, optimal survival in lungs of mice and guinea pigs, resistance to the action of CAMPs and for maintaining optimal membrane potential (Maloney et al., [@B18]).

While the above study shows that *lys*X plays an important role in *M. tuberculosis* survival upon infection, several questions remain with respect to *lys*X *in vivo* phenotype. For example, these studies revealed that lysinylated phosphatidylglycerol (L-PG) is a constituent of *M. tuberculosis*, although it is unknown if other mycobacterial species also produce lysinylated phospholipids (L-PL). Also, the *lys*X complement strain, wherein *lys*X expression was achieved from *M. smegmatis* amidase promoter (Triccas et al., [@B38]), was partially proficient in restoring *lys*X defect (Maloney et al., [@B18]). While studies based on fluorescent probes allowed the visualization of acidic phospholipids such as PG and CL in *Escherichia coli* and other bacteria as defined domains (Kawai et al., [@B16]; Romantsov et al., [@B32]; Mileykovskaya and Dowhan, [@B20]), it is unknown whether the absence of L-PG production is associated with changes in membrane lipid domain organization and possibly their turnover thereby contributing to the observed changes in membrane potential (Maloney et al., [@B18]). The present study is undertaken to address some of these issues.

We found that the domain organization of the major acidic phospholipid CL, as revealed by 10-nonyl acridine orange (NAO) staining, is not significantly affected in *lys*X mutants. However, differences in the turnover of select membrane phospholipids were found between *lys*X and its parent. Furthermore, our results indicate that expression of *lys*X from a strong inducible tet promoter allowed full complementation *in vivo* and that radiolabeled lysine is incorporated in other mycobacterial phospholipids. Our studies favor a hypothesis that alterations in phospholipid turnover are in part responsible for the observed *lys*X phenotype.

Materials and Methods {#s1}
=====================

Cloning
-------

Unless otherwise noted all genes used in this study were generated by polymerase chain reaction (PCR) using genomic DNA as a template and Phusion DNA polymerase (New England Biolabs). As needed, PCR products were Taq polymerase treated, cloned into pGEM T-easy (Promega) prior to subcloning in other plasmids. *Escherichia coli* TOP10 cells were used to transform plasmids and the transformants were selected on LB agar containing 100 μg/mL ampicillin, 0.1 M IPTG, and 40 μg/mL X-gal.

Construction of *lys*X complement strains
-----------------------------------------

We wished to express *lys*X from tetracycline (*Ptet*) and nitrile (*Pnit*A) inducible promoters (Ehrt et al., [@B8]; Pandey et al., [@B24]) and created respective complement strains (see below). For placing *lys*X coding region under *Ptet* oligonucleotide primers bearing *Pac*I and *Swa*I sites, 5′-AGAACCTTAATTAAAGCCCCACCAGGGAGGAAGCCGAACGATGGGACTCCACTTAA-CTG-3′ and 5′-ATCGGATTTAAATCTAATGCGGTTTTGCCAAC-3′, respectively, were used to amplify *lys*X gene, cloned into pLR56 (Dziedzic et al., [@B7]), which is a pMV306 based integration proficient vector bearing *tet*R- and tetO-containing mycobacterial promoter. Plasmids containing *tet*R- and *tetO-*containing mycobacterial promoter are a kind gift from Dr. Sabine Ehrt (Ehrt et al., [@B8]). Similarly, oligonucleotide primers 5′-CACCTCGTACTGTCCTGCCAA-3′ and 5′-CGCCGCGTTGAA-GTCGGC-3′ were used to clone *lys*X gene under *Pnit*A. Both recombinant plasmids were used to transform the previously constructed *lys*X full gene *Pami* complement strain. In this strain, the chromosomal copy of *lys*X was replaced with a copy that has been disrupted by a gentamycin resistance gene; a second copy of *lys*X was integrated at the *attB* locus using a hygromycin resistant integrating vector. The *Ptet* construct or the *PnitA* construct bearing the *lys*X gene replaces the integrated hygromycin resistant vector at the attB site via swapping (Rajagopalan et al., [@B29]), thus creating *Ptet* and *PnitA* controlled complement strains designated as *Ptet-lys*X and *PnitA-lys*X, respectively. As previously described (Maloney et al., [@B18]), the *lys*X mutant strain was created by replacing the integrated copy of *Pami-lys*X with an empty vector at the attB site. These strains were confirmed by PCR.

Construction of *M. smegmatis* overexpression strains
-----------------------------------------------------

For overexpression of *M. tuberculosis lys*X and Rv1639c genes in *M. smegmatis*, oligonucleotide primer combinations mvm530*lys*XF (5′-GGCGAATTCCATATGGGACTCCACTTAACTG-3′) and mvm531*lys*XR (5′-CCTACGGTCTAGACTAATGCGGTTTTGCAACGG-3′) for *lys*X and MR149F (5′-GGAATTCCATATGGCTCAGAATGAACTGTGAC-3′) and MR150R (5′-ATCGGTCTAGAATTTAAATCTATCTGCCGGTACCGGCGATCTG-3′) for Rv1639c, were used and the respective genes were cloned under *Pami* promoter. The resulting constructs were transformed into *M. smegmatis* MC^2^155 and the merodiploid strains were characterized further.

Growth of bacterial strains
---------------------------

*Escherichia coli* strains were grown in Luria--Bertani media, whereas *M. smegmatis* MC^2^155 and *M. tuberculosis* H37Rv strains were grown in Middlebrook 7H9 media (Becton--Dickenson) supplemented with albumin (5 g/L) and dextrose (2 g/L); in addition, *M. tuberculosis* cultures were supplemented with oleic acid (60 μL/L) and catalase (3 mg/L). Kanamycin (Sigma-Aldrich) at 25 μg/mL for *M. smegmatis* and 10 μg/mL for *M. tuberculosis* were used whereas hygromycin (Roche) at a final concentration of 50 μg/mL for both strains. In some experiments, Polymyxin B (PMNB; Sigma-Aldrich) was added to cultures at a final concentration of 500 units/mL for *M. tuberculosis*. For growth attenuation studies in *M. smegmatis*, PMNB was added to either 130 or 195 U/mL, vancomycin to either 5 or 10 μg/mL and lysozyme to 20 μg/mL; these concentrations were chosen using published MICs for *M. smegmatis* strains as a guideline. (Peteroy et al., [@B27]; Yasue, [@B39]; Raymond et al., [@B30]). For evaluation of *lys*X expression from the *Pnit*A and *Ptet* promoters, tetracycline (25 ng/mL) or isovaleronitrile (10 nM) was added to growth media. Growth curves were generated by reading the optical density (600 nm).

Reverse transcription and real-time PCR
---------------------------------------

Extraction of RNA using RNA Bee (Tel-Test, Inc.) and chloroform and quantitative real-time PCR were essentially as previously described (Chauhan et al., [@B3]; Fol et al., [@B10]; Maloney et al., [@B18]). cDNA transcripts of interest were reverse transcribed at 42°C from total isolated RNA using the SuperScript II RT kit (Invitrogen); each reaction contained 0.25 mM each dNTP, 1× First Strand Buffer, 10 mM DTT, RNaseOUT (4 U/μL, Invitrogen), 0.6 μM gene specific RT primer, and 100 units SuperScript II reverse transcriptase. Gene specific RT primers are listed in Table [1](#T1){ref-type="table"}. For each sample, identical reactions were performed without reverse transcriptase to confirm the absence of contaminating genomic DNA as described previously (Chauhan et al., [@B3]; Fol et al., [@B10]; Maloney et al., [@B18]). The transcribed cDNA was used as template for real-time PCR reactions containing 0.5 μM each of the primer and probe set for the transcript of interest, 0.15 μM each of primers and probe for the control transcript 16S rRNA, 0.25 mM each dNTP, 1.5 mM magnesium chloride, 1× Taq buffer, and 0.2 units/15 μL Taq polymerase (New England Biolabs). Primers and Taqman probes are listed in Table [1](#T1){ref-type="table"}.

###### 

**Primers and Taqman probes used for real-time PCR**.

  Primer name          Sequence
  -------------------- -------------------------------
  *lys*X RT            5′-GAATACCACCGACTTGTCGCG-3′
  *lys*X F             5′-TCGTGGCGTCTTGGGGTCTGGTC-3′
  *lys*X R             5′-CGAACGCGCCGAACAACCCGAAG-3′
  *lys*X TP            5′-FAM-CGGGATCACTAGCGCCGGACG
                       AGCGGTTGG-BHQ-3′
  Rv1639 RT            5′-CCGGAATCCACGAATACCA-3′
  Rv1639 F             5′-GATCAGGCCGCTGTTGC-3′
  Rv1639 R             5′-ATGCTCTCGGTCGAACCAG-3′
  Rv1639 TP            5′-FAM-TACACCAGTTCGCCGCGATGC
                       TTGAAGT-BHQ-3′
  RT16s3 (RT primer)   5′-CCGCACGCTCACAG-3′
  RT16s1 (forward)     5′-GAGTGGCGAACGGGTGAGTAACA-3′
  RT16s2 (reverse)     5′-CACCCCACCAACAAGCTGATAGG-3′
  RT16sTP              5′-BHQ-TCCACCACAAGACATGCATCC
                       CGTG-Q670-3′

"*F*" *denotes forward primers, "R" is reverse, and "TP" designates Taqman probes. In the Taqman probe sequences, "FAM" and "Q670" are the fluorescent tags and "BHQ" is the quencher molecule*.

Fluorescence microscopy methods
-------------------------------

10-Nonyl acridine orange was added directly to media during growth of cultures for either 1 h (for *M. smegmatis*) or 24 h (for *M. tuberculosis*) prior to harvesting cells for microscopy. *Mycobacterium tuberculosis* pellets were suspended in 4% paraformaldehyde and stored at 4°C for 24 h before imaging. For NAO staining and visualization *M. smegmatis* and *M. tuberculosis* cells were resuspended in fresh media. Stained cells were examined by brightfield and fluorescence microscopy using a Nikon Eclipse E600 microscope with an attached CoolSnap ES CCD camera (Photometrics) and high-pressure mercury lamp (Nikon). NAO-stained cells were imaged using a custom NAO filter set (Ex450-490/Em645, Chroma Technology) for red fluorescence and the Nikon B2A filter set for green fluorescence. Images were analyzed using MetaMorph 6.2 software (Universal Imaging Corporation).

Aerosol infection of mice
-------------------------

All animal procedures were approved by the Johns Hopkins University Animal Care and Use Committee. Six-week-old female BALB/c mice (Charles River) were aerosol infected with *M. tuberculosis* *lys*X mutant, *Ptet* complement, and the wild-type strain using the Middlebrook inhalation exposure system (Glas-Col) with log-phase broth cultures. To induce the expression of *Ptet* complement and for fair comparison across groups, all mice were given medicated water containing 1 mg/mL of doxycycline and 5% sucrose in light protected bottle (Gandotra et al., [@B12]). Water was changed two times per week. At days 1, 7, 14, 28, 56, 84, and 112 post-infection, four mice from each group were sacrificed and the lungs and spleens were collected. The lung and spleen gross pathology, lung and spleen weights and body weights were recorded. From each mouse, one lung was homogenized and the supernatants were collected for cytokine profiling; the other lung was collected for colony-forming unit (CFU) enumeration with small portions collected and fixed with 10% formalin for histopathology study. The CFUs per lung or spleen were determined by plating diluted lung or spleen homogenates onto 7H11 selective agar.

^14^C-acetic incorporation and phospholipid analysis
----------------------------------------------------

*Mycobacterium tuberculosis* cultures (10 mL × 8 flasks) were grown to OD~600~ 0.2 and ^14^C-acetate was added to a final concentration of 0.5 μCi/mL and cultures were grown for 24 h. At the end of incubation, cultures were harvested, washed with fresh prewarm media two times. One set of culture was removed for lipid extraction. Other culture pellets following washing in radioactive media were resuspended in fresh media containing 12 mM sodium acetate. After 12-, 24-, and 48-h incubation, cultures in duplicate were harvested, washed, and processed for lipid extraction. *Mycobacterium tuberculosis* cultures grown without radiolabeled acetic acid were mixed with radiolabeled cultures prior to chloroform--methanol extraction. The amount of ^14^C-acetate incorporated into lipid fractions was determined by scintillation counting. Approximately, equal counts of polar lipid fractions were loaded on to thin-layer chromatography (TLC) plates (Gel 60 F~254~, 20 cm × 20 cm, 250 μm, EMD \#5715-7, 20 cm × 20 cm) resolved by TLC in a solvent system of chloroform:methanol:water (65:25:4 v/v/v) along with phosphatidylethanolamine (PE), PI, and CL of *M. tuberculosis* standards. Lipids were visualized followed by ninhydrin staining, bands corresponding to individual lipids were identified, scraped, extracted with chloroform:methanol, dried, and counted. Each spot in duplicate from two independent cultures were averaged and SD was estimated.

Statistical analysis
--------------------

Differences between data sets were analyzed using Student\'s *t*-test. A *P* value of \<0.01 was considered to be significant.

Results and Discussion
======================

Evaluation of *lys*X expression from the tetracycline inducible promoter
------------------------------------------------------------------------

Earlier experiments designed to evaluate *lys*X phenotype used a complement strain wherein *lys*X gene was expressed from a constitutively active *M. smegmatis ami* promoter and this strain was designated as *ami-lys*X (Maloney et al., [@B18]). It is known that *M. smegmatis ami* promoter is inducible in *M. smegmatis*, but is rather constitutively expressed in *M. tuberculosis* (Chauhan et al., [@B3],[@B4]; Fol et al., [@B10]). As reviewed, absence of *lys*X function led to membrane hyperpolarization, which in turn sensitized the pathogen to lipophilic antibiotics and CAMPs. The *lys*X mutant was also found to be defective for proliferation in macrophages and mice lungs (Maloney et al., [@B18]). While the *ami-lys*X complement strain was proficient in reversing *lys*X defect in most of the assays tested, *albeit* partially, it was defective in restoring *lys*X defect *in vivo*. Global gene expression profile studies by other investigators also indicated that *lys*X is one of the upregulated genes during acute and chronic infections (Talaat et al., [@B35]). Hence, we considered a possibility that *lys*X expression from heterologous *amidase* promoter is not optimal *in vivo* and the use of strong alternate promoters, such as tetracycline inducible promoters, could restore *lys*X phenotype. Another alternative is to express *lys*X from its native promoter to avoid issues associated with gene expression. The promoter elements controlling *lys*X gene have not been defined, and thus in the absence of this information, we chose to proceed with the best characterized *Ptet* promoter. Alternatively, disruption of *lys*X at its native locus could be affecting expression of downstream genes, thereby contributing to the observed phenotype. Both possibilities are not mutually exclusive.

To begin addressing these issues we first examined if *lys*X expression was elevated upon infection by quantitative real-time PCR. Analysis of *lys*X transcript levels relative to 16S rRNA from broth and intracellularly grown *M. tuberculosis* revealed that *lys*X expression was elevated about fourfold (4.1 ± 0.42) relative to broth during intracellular growth in monocyte derived macrophages or in THP-1 macrophages (not shown). Next, in an attempt to express *lys*X from strong inducible promoters, we constructed two plasmids wherein *lys*X expression was induced from *tet* and *nit*A promoters and created appropriate complement strains, *Ptet-lys*X and *PnitA-lys*X, respectively (see [Materials and Methods](#s1){ref-type="sec"}) and evaluated *lys*X expression levels relative to control and that expressed from *Pami* (Figure [1](#F1){ref-type="fig"}). As can be seen, *lys*X expression in *Ptet-lys*X complement was about 10-fold (*P* = 0.003) more than that in the wild-type strain when tetracycline was added to the growth media and about fourfold (*P* = 0.002) higher when cells were grown without tetracycline. The latter result also indicated that the *Ptet* promoter under our experimental conditions is leaky. We also found that *lys*X expression in *Pnit*A-*lys*X complement strain following the addition of isovaleronitrile (10 nM) was moderately less as compared to wild type indicating that the inducer isovaleronitrile was inhibiting *lys*X expression. However, there was no growth inhibition at the concentration of inducer used (data not shown). Expression of *lys*X in the *Pami-lys*X complement was similar to that of the wild-type strain (*P* = 0.211) both in the absence and presence of acetamide. It has been shown that select gene expression from the *Pami* in *M. tuberculosis* is constitutive and is not robust (Chauhan et al., [@B3],[@B4]; Fol et al., [@B10]). Hence, we conclude from these results that *lys*X expression from *Ptet* could lead to elevated or optimal levels of *lys*X and hopefully could restore *lys*X phenotype *in vivo*. Accordingly, the *Ptet-lys*X strain was further characterized *in vitro* and *in vivo*.

![**Expression of *lys*X in *M. tuberculosis* strains**. Wild-type *M. tuberculosis* (WT) and the *Pami* (ami), *Ptet* (Tet), and *Pnit*A (*nit*A) complement strains were used for RNA extraction. The *Ptet* complement was grown with (Tet+) and without (Tet−) tetracycline whereas the *Pnit*A strain was grown with isovaleronitrile. Expression of *lys*X was evaluated by real-time PCR using RNA isolated from each strain; these results were normalized against expression of 16s rRNA. *lys*X expression in the wild-type strain is assigned a value of 1 and all other results are shown as fold change relative to this value. All values are the means ± SD from two independent experiments with triplicate samples; single star represents *P* \< 0.01 versus WT (Student\'s *t*-test). Note *lys*X expression from *Pnit*A promoter was moderately less as compared to that in wild type (*P* = 0.068).](fmicb-02-00019-g001){#F1}

The effect of pmnb on survival of *Ptet-lys*X complement strain
---------------------------------------------------------------

We have previously shown that the *lys*X mutant is sensitive to PMNB, a CAMP whereas *Pami-lys*X complement is as proficient for survival as the wild type at 100 units/mL of PMNB (Maloney et al., [@B18]). However, the *Pami-lys*X is only partially proficient for survival at higher doses of PMNB (data not shown). To test if *Ptet-lys*X complement reverses *lys*X sensitivity to PMNB at higher doses, we grew *M. tuberculosis* strains in the presence of 500 units/mL PMNB and recorded change in optical density as a measurement of growth (Figure [2](#F2){ref-type="fig"}). The *Ptet-lys*X complement grew in a manner similar to wild type whereas *lys*X mutant showed moderate growth defect in the absence of PMNB. However, in the presence of 500 units/mL PMNB *Ptet-lys*X complement grew better than that of the *Pnit-lys*X and *Pami-lys*X, indicating that the *Ptet-lys*X reverses growth defect significantly due to PMNB.

![**Growth of *M. tuberculosis lys*X** **strains and the effect of Polymyxin B**. The *M. tuberculosis* wild type (WT), *lys*X mutant (mut), and the *lys*X *Pami* (ami), *lys*X *Ptet* (tet), and *lys*X *Pnit*A (nitA) complement strains were grown in media alone **(A)** and in media supplemented with Polymyxin B 500 units/mL **(B)**; optical density measured at 24 h intervals. All values are the means ± SD from three independent experiments.](fmicb-02-00019-g002){#F2}

Expression of downstream gene Rv1639C in *lys*X mutant
------------------------------------------------------

The *lys*X mutant strain we created by homologous recombination lacks most of the *lys*X coding region. Genome sequence analysis revealed that the immediate downstream gene, Rv1639c, is separated from *lys*X by less than 60 nucleotides and the Rv1639c-*lys*X intergenic region lacks typical mycobacterial promoter features. Although not proven, *lys*X and Rv1639c genes could be polycistronic. Accordingly, we evaluated the expression levels of Rv1639c in *lys*X mutant relative to wild type and its complement derivatives *Pami-lys*X and *Ptet-lys*X strains. As can be seen, removal of *lys*X did not inhibit Rv1639c expression and in fact upregulated its expression approximately sevenfold (*P* = 0.0007; Figure [3](#F3){ref-type="fig"}). The Rv1639c expression levels restored to wild-type levels in *Ptet-lys*X complement strain (*P* = 0.128). Rv1639c expression was elevated two- to threefold in *pami-lys*X (*P* = 0.004; Figure [3](#F3){ref-type="fig"}). The function of Rv1639c gene product in *M. tuberculosis* metabolism is unknown, but Tuberculist gene annotation data indicate that it contains PS00904 protein phenyltransferase alpha subunit signature motif. It is tempting to speculate that the two-domain lysyltransferase-lysyl-tRNA synthetase protein negatively regulates Rv1639c expression. It remains to be evaluated how *lys*X activity is involved in regulating Rv1639c expression.

![**(A)** Expression of *Rv1639c* in *M. tuberculosis lys*X strains. Expression of *Rv1639c* was evaluated by real-time PCR using RNA isolated from Wild-type *M. tuberculosis* (WT), the *lys*X mutant (Mut) and both the *Pami* (Ami) and *Ptet* (Tet) complement strains, and results were normalized against expression of 16s rRNA as described above. All values are the means ± SD from two independent experiments with triplicate samples; single star represents *P* \< 0.01 and double stars indicate *P* \< 0.001 versus WT (Student\'s *t*-test). **(B)** Antibiotic sensitivity of *M. smegmatis* merodiploid strains overproducing Rv1639 and *Lys*X proteins. Cultures were grown in the presence or absence of either **(A)** Polymyxin B 130 and 195 U/mL, or **(B)** vancomycin 5 μg/mL, 10 μg/mL (VAN5, VAN10). Bars represent absorbance values for each culture. The values represented are the means ± SD for four independent samples; stars represent *P* \< 0.01 compared with the control culture (-) for each (Student\'s *t*-test).](fmicb-02-00019-g003){#F3}

The above results, although unlikely, raise a question as to whether overexpression of Rv1639c is responsible for the observed *lys*X phenotype (Maloney et al., [@B18]). Bioinformatics analysis indicated that both *lys*X gene and the organization of its immediate flanking regions including Rv1639c are very conserved in *M. smegmatis* and other mycobacterial members. Furthermore, Rv1639c gene product and its *M. smegmatis* counterpart MSMEG3797 are 58% identical and 83% similar. Thus, to address the above issue we created *M. smegmatis* merodiploids overexpressing Rv1639c and *lys*X and evaluated their sensitivity toward CAMP relative to wild type (Figure [3](#F3){ref-type="fig"}B). If overexpression of Rv1639c has deleterious effect, then *M. smegmatis* overexpressing Rv1639c would be expected to be sensitive to CAMP. As can be seen, *M. smegmatis* merodiploid overexpressing Rv1639c is no more sensitive to PMNB and Van than the wild type (Figure [3](#F3){ref-type="fig"}B). Similar results were also noted with lysozyme (data not shown). We also found that *M. smegmatis* merodiploid overexpressing *lys*X is some what more sensitive to PMNB than that of the Rv1639c and wild type. We have not investigated the consequences of artificial overexpression of Rv1639c on *M. tuberculosis* survival in mice lungs. Nonetheless, our results suggest that overexpression of Rv1639c does not contribute to the observed *lys*X phenotype.

Survival of *M. tuberculosis lys*X (Rv1640C) and *Ptet-lys*X in mouse lung
--------------------------------------------------------------------------

In order to evaluate if *Ptet-lys*X is proficient in restoring *lys*X virulence phenotype, we infected Balb/c mice with an inoculum of similar size for wild type, *lys*X mutant and *Ptet-lys*X (10 mL of log-phased cultures containing 6.90-, 7.00-, and 6.91-log CFU/mL). After aerosol infection, CFUs were compared for bacteria isolated from mouse lung. Both wild-type and *Ptet-lys*X complement grew approximately 2 logs, while only minor growth was seen for the *lys*X deletion mutant (Figure [4](#F4){ref-type="fig"}A). At days 14, 28, and 112, CFU in the lungs of *lys*X deletion mutant was significantly lower than that of wild type or *Ptet-lys*X. The *lys*X mutant also showed reduced dissemination to the spleen, as shown by the lower CFU counts relative to wild type (Figure [4](#F4){ref-type="fig"}B). Partial restoration of the CFU counts in the spleen was seen for *Ptet-lys*X complement. Gross pathology showed slightly more apparent granulomas in the wild-type and *Ptet-lys*X complement lungs compared with the deletion mutant (Figure [5](#F5){ref-type="fig"}A). However, there was no significant difference in body weight, lung weight, and spleen weight (data not shown). Histopathology studies showed more functional alveolar sacs in the *lys*X mutant lungs than in the wild-type and *Ptet-lys*X complement lungs, with the wild-type lungs showing the most severe lesions as exemplified by consolidation, inflammatory cell infiltration, and nodule-like loci formation (Figure [5](#F5){ref-type="fig"}B).

![**(A)** Growth of *Mycobacterium tuberculosis lys*X deletion mutant (Δ*lys*X), *lys*X tet complement (Comp), and wild-type (H37Rv) in mouse lungs after low-dose aerosol infection. Groups of 28 mice were implanted at day 1 with 3.2- (Δ*lys*X), 3.5- (Comp), and 3.6-log (H37Rv) colony-forming units (CFU) in the lungs. **(B)** Growth of *Mycobacterium tuberculosis* in mouse spleens after low-dose implantation. Animals were infected via aerosol with *M. tuberculosis lys*X deletion mutant (Δ*lys*X), *lys*X tet complement (Comp), and wild-type (H37Rv) strains. Groups of 28 mice were implanted at day 1 with 3.2- (Δ*lys*X), 3.5- (Comp), and 3.6-log (H37Rv) CFU in the lungs.](fmicb-02-00019-g004){#F4}

![**Mouse lung gross pathology and histopathology at day 112 after infection**. **(A)** Gross pathology of the lungs infected with the *M. tuberculosis* *lys*X mutant (top row), *lys*X tet complement (middle), and wild-type (bottom) strains. **(B)** Lungs from mice were excised, stored in 10% formalin, embedded, and stained with hematoxylin and eosin for histopathological analysis. Hematoxylin-eosin staining confirmed that the lungs infected with wild-type and the *lys*X tet complement had extensive inflammation, but not those infected with the *lys*X mutant.](fmicb-02-00019-g005){#F5}

These results showing reduced lung pathology in *lys*X mutant relative to wild type suggest that *lys*X is required for full virulence in the mouse infection model. Introduction of a wild-type copy of this gene expressing from *tet* promoter restored most of the phenotype, unlike complementation with *Pami-lys*X (Maloney et al., [@B18]). We also found an overall lower than expected bacterial growth in the mouse lungs of all strains. One possibility is that the continuous propagation of *M. tuberculosis* H37Rv strain decreases overall ability to replicate in mice lungs and possibly its virulence potential. In all our experiments, doxycycline was added to all cultures throughout the infection period; doxycycline, has shown to be required for optimal gene expression from the Tet-ON promoter *in vivo* (Gandotra et al., [@B12]). Presumably, addition of doxycycline could have impacted the growth of all strains. It is not evident whether the concentration of doxycycline used to affect gene expression has any effect on immunity and this has not been addressed in this study. This limitation, however, did not impact our overall finding that *lys*X mutant showed lower CFU counts in mice lungs as compared to wild-type and *Ptet-lys*X complement strains. Together, these results showing the restoration of *lys*X defect by *Ptet-lys*X confirm that the observed growth defect phenotypes are specific to *lys*X.

*Lys*X mutant and phospholipid domains
--------------------------------------

Next, to evaluate the correlation between altered membrane potential and *lys*X phenotype, we characterized *lys*X strain with respect to organization of major membrane phospholipids and their turnover. Earlier studies showed that L-PG is a minor phospholipid constituent and that its absence is associated with an increase in membrane potential (Maloney et al., [@B18]). In mycobacteria PG is a minor phospholipid species and is the biosynthetic intermediate for diphosphatidylglycerol, CL, which is one of the most abundant phospholipid (Brennan and Nikaido, [@B1]). Recent studies on the interactions of bacterial membranes with fluorescent dyes indicate that membranes are organized into distinct domains containing lipids (Kawai et al., [@B16]; Romantsov et al., [@B32]; Mileykovskaya and Dowhan, [@B20]). Among these dyes, NAO, a hydrophobic fluorescent dye, has been generally used to mark polar acidic PL and specifically CL. NAO has been shown to bind CL in mitochondrial membranes with a ratio of 2:1, creating a stacked pair that is dimer-like. As the monomer form becomes less abundant and the number of stacked pairs increases, absorption shifts from 495 to 474 nm; this is accompanied by a shift in the emission from green (525 nm) to red (640 nm). Thus, binding of NAO to CL, but not to other acidic phospholipids, promotes a green to red shift in fluorescence (Petit et al., [@B28]; Gallet et al., [@B11]; Mileykovskaya et al., [@B21]; Mileykovskaya and Dowhan, [@B20]).

To visualize CL membrane lipid organization in *lys*X mutant we stained *M. tuberculosis* cells with NAO. It has been reported that in actively growing bacterial cells CL enriched domains are present at poles and near potential cell division sites and that changes in CL levels affect CL domain organization in membranes (Kawai et al., [@B16]; Mileykovskaya and Dowhan, [@B20]). Membrane lipid domains in mycobacteria have not been analyzed using NAO dye, hence, we first asked if NAO is a suitable marker stain for visualizing membrane lipid domains in *M. tuberculosis*. Since visualization of CL by NAO staining requires culturing cells in growth media containing dye, it was necessary to evaluate the effects of NAO on *M. tuberculosis* growth. We found concentrations up to 500 nM NAO did not interfere with growth (Figure [6](#F6){ref-type="fig"}A). We then examined NAO-stained cells of *M. tuberculosis* (Figure [6](#F6){ref-type="fig"}B) following paraformaldehyde fixation by fluorescence microscopy. Although staining was diffuse, distinct bright patterns of fluorescent spots are evident at poles and mid cell septa when visualized using both green and red filter sets (see [Materials and Methods](#s1){ref-type="sec"}). Interestingly, red spots overlap with green indicating that these regions are where CL is enriched. The diffuse staining pattern could be a consequence of paraformaldehyde fixation, which is a required step to visualize *M. tuberculosis* in BSL3 setting. To visualize NAO-stained CL under non-fixation conditions, we examined NAO-stained cells of *M. smegmatis*, a non-pathogenic bacteria (Figure [6](#F6){ref-type="fig"}C). These cells showed rather sharp green and red spots primarily localized at mid cell septa and poles confirming that the localization patterns of CL in both mycobacterial species are similar. We also found that stationary phase grown cells of *M. smegmatis* were poorly stained (Figure [6](#F6){ref-type="fig"}D). Presumably, NAO readily stains newly synthesized CL. It is unlikely that the stationary phase grown cells lack CL, but is likely that CL turn over in actively growing cells is relatively high as compared to that in stationary phase cells.

![**NAO staining in mycobacteria**. **(A)** Effect of NAO addition to culture media during growth of *M. tuberculosis*. *Mycobacterium tuberculosis* cultures were grown in media with and without the NAO stain and optical density (OD 600 nM) measured at 24 h intervals. All values are the means ± SD. **(B)** *M. tuberculosis* cultures were stained with the lipid dye nonyl acridine orange (NAO) during active growth by adding the dye to the growth media (100 nM final concentration) for 24 h prior to harvest. Cells were then fixed in paraformaldehyde and observed by fluorescence microscopy. Grayscale images show brightfield illumination of cells; green fluorescence images show NAO staining of monoacidic phospholipids and red fluorescence images represent NAO staining in regions where cardiolipin is present. **(C,D)** NAO staining of *M. smegmatis* during active growth and stationary phase, respectively. Active cultures growing at an OD600 of 0.2 were supplemented with 100 nM NAO and incubated for 2 h at 37°C. *Mycobacterium smegmatis* cultures grown for overnight to an OD~600~ of 3.5 are referred to as stationary phase cells. NAO was added and incubated for 2 h at 37°C; live cells were removed from the cultures and directly observed by fluorescence microscopy. All images were taken at 100× magnification with scale bars representing 3 μm.](fmicb-02-00019-g006){#F6}

Nao staining of *lys*X mutant
-----------------------------

Next we stained *lys*X mutant with NAO and visualized by microscopy (Figure [7](#F7){ref-type="fig"}). The following results are evident. First, visualization of cells by bright field microscopy revealed that *lys*X mutant cells were elongated compared to wild type. The average cell length determined from 200 cells of *lys*X mutant is 3.1 μM, whereas that for wild-type cells is 2.5 μM. Differences in cell length tend to suggest defects in cell division. Second, we found that more *lys*X cells were stained presumably due to increased permeability. Third, there appear be differences in the NAO staining pattern between the wild-type and *lys*X mutant. Some *lys*X mutant cells contained distinct spots not only at presumptive mid cell positions, but also at the three-quarter or daughter cell position. The number of NAO spots at poles in wild-type and *lys*X mutants were similar, however, those at mid cells and quarter position are more for *lys*X mutant relative to wild type (Figure [7](#F7){ref-type="fig"}). Also, NAO spots in *lys*X mutant are generally brighter as compared to wild type. Increased permeability of *lys*X mutant cannot explain the differences in the NAO staining patterns between the strains because a general increase in permeability would be expected to show a corresponding increase in the frequency of polar staining as well as that seen for mid and quarter cell.

![**Cardiolipin staining of the *M. tuberculosislys*X mutant**. **(A)** Cultures were stained with NAO as described above, cells were fixed in paraformaldehyde and observed using fluorescence microscopy. Images I and III are brightfield 100× magnification, with scale bars representing 3 μm. Images II and IV show NAO bound to regions where cardiolipin is present. **(B)** Fluorescence images of NAO-stained cells were analyzed and type of staining was recorded for about 200 cells from each strain.](fmicb-02-00019-g007){#F7}

Major phospholipid turnover in *lys*X mutant
--------------------------------------------

Next we evaluated the degradation and turnover of major phospholipids in *lys*X mutant following incorporation of ^14^C-acetic acid into chloroform--methanol soluble lipids. Wild-type and *lys*X mutant cells were cultured with ^14^C-acetate, relative levels of CL, PE, and PI were determined following TLC analysis and autoradiography (Maloney et al., [@B18]). Significant reduction in the levels of PI between *lys*X (5.2%) and wild-type parent (7.2%) was noted (*P* value ≤0.02) whereas no significant differences in the levels of CL and PE were noted between the two (data not shown). We did however find differences in the turnover of PE and PI between the strains. While both *lys*X and wild type showed similar rates of turnover for CL, the turnover rates for PE and PI were slower in *lys*X mutant as compared to wild type (see Figure [8](#F8){ref-type="fig"} and legend for *P* values). Notably, PE in *lys*X mutant did not exhibit appreciable turnover over the time period followed. Presumably, decreased turnover rates of PE and PI relative to wild type could be contributing to the changes in the membrane potential and possibly affecting the cell division process.

![**Turnover of *M. tuberculosis* phospholipids following ^14^C-acetic acid incorporation**. Total lipids were extracted and analyzed by TLC. Radioactive spots corresponding to each phospholipid were identified, lipids were extracted and radioactivity present in each spot was measured by scintillation counting. Closed symbols stand for Δ*lys*X and open ones correspond to RvWT. **(A)** represents changes in the level of PI, **(B)** PE, and **(C)** CL. Data are presented as percentage of total lipids, relatively to time zero. Values were obtained from two independent experiments in duplicate. The star represents *P* \< 0.02 and hash *P* \< 0.05 (*t*-test method). The values represent averages and bars indicate the SD.](fmicb-02-00019-g008){#F8}

Lysinylated pl are also present in other mycobacteria
-----------------------------------------------------

*Lys*X appears to be a conserved protein in all mycobacterial species that have been examined to date. *Lys*X is a two-domain fusion protein containing N-terminal lysyltransferase (626 aa) and C-terminal lysyl-tRNA synthetase. Amino acid sequence analysis, including closely related family member *Corynebacterium glutamicum*, revealed that the *Lys*X protein in mycobacteria shows significant sequence similarity, although differences in the N-terminal portion of these proteins (data not shown). Considering the similarities in the primary sequence, we asked if there are any differences in the distribution of L-PL in mycobacteria. To address this question, we cultured *M. smegmatis*, *M. avium*, and avirulent *M. tuberculosis* H37Ra in the presence of ^14^C-lysine, extracted total lipids and were analyzed as described (Maloney et al., [@B18]; Figure [9](#F9){ref-type="fig"}). As can be seen, ^14^C-lysine was incorporated in all mycobacterial species, however, the mobility of L-PL of *M. tuberculosis* strains is different from *M. avium* and *M. smegmatis*. Interestingly, one additional spot unique to *M. avium* was identified (Figure [9](#F9){ref-type="fig"}, see lane corresponding to *M. avium*). Presumably, differences in the N-terminal region of the *Lys*X protein could contribute to these differences. It is likely the activities and possibly turnover of L-PG are different from virulent and avirulent mycobacterial species.

![**Polar lipid profiles of mycobacterial strains**. Strains were grown in the presence and absence of ^14^C-lysine, total lipids were extracted in chloroform:methanol (2:1 v/v) and resolved by TLC in solvent system of chloroform:methanol:water (65:25:4 v/v/v).](fmicb-02-00019-g009){#F9}

In summary, our results confirm that *lys*X activity is required for resisting the action of CAMP and for expression of full virulence in mice. Since *lys*X transcript levels are elevated during intracellular growth, we reason that optimal survival of *M. tuberculosis* upon infection requires elevated expression levels of *lys*X and that this higher level expression could be attained in *Ptet-lys*X, but not in *Pami-lys*X. This could explain why *Pami-lys*X is not competent at restoring *lys*X phenotype optimally (Maloney et al., [@B18]).

There are three interesting and possibly related findings in this study. First, CL enriched regions are found to be present at mid cells and poles of actively dividing mycobacterial cells, but not in stationary phase cells. Second, the turnover rates of PE and PI, but not CL, in *lys*X mutant are found to be significantly different from that of wild type. Third, *lys*X mutant is elongated indicating a defect in cell division. It is pertinent to know that localization of CL near nucleoid-free poles and growing septa has been reported in other bacteria as well (Mileykovskaya and Dowhan, [@B19], [@B20]; Romantsov et al., [@B32]). Although, we have not examined in this study, it is known that zwitterionic phospholipid PE, also localizes in the polar septa and septal membranes of other bacteria that have been examined (Nishibori et al., [@B22]). Mutations in genes affecting phospholipid metabolism have been shown to delay cell division and produce filamentous cells (Nishijima et al., [@B23]; DeChavigny et al., [@B6]). Thus, it is likely that septal localization of CL and possibly other phospholipids and cell division go together in mycobacteria. It remains to be explored how *lys*X activity affects phospholipid turnover rates and cell division in *M. tuberculosis*, and if both processes are connected. Presumably, optimal turnover of membrane phospholipids is necessary for regulated cell cycle progression and the maintenance of membrane potential necessary for *M. tuberculosis* multiplication upon infection and other stressful growth conditions. It is known that PG is accumulated as a consequence of CL catabolism (Bright-Gaertner and Proulx, [@B2]; Short and White, [@B33]). Presumably, optimal PG lysinylation mediated by *Lys*X and its delysinylation step by hitherto unidentified enzymes could modulate membrane lipid turnover and this may in turn influence membrane potential and cell division. Finally, it is known that the complex lipid-rich *M. tuberculosis* cell envelope enables the pathogen to resist host defense mechanisms (Brennan and Nikaido, [@B1]). *Mycobacterium tuberculosis* phospholipids are known to function as immune modulators (Grant et al., [@B15]); often released during intracellular growth and are transported to lysosomes for possibly modulating their function (Fischer et al., [@B9]; Geisel et al., [@B13]; Rhoades et al., [@B31]). Accordingly, one can also envision that changes in phospholipid turnover affects phospholipid ability to function as effective immune modulators, which could in turn influence *M. tuberculosis* multiplication upon infection. Detailed studies on phospholipid metabolism in *lys*X mutant and its contribution in cell division could provide valuable clues as to how *lys*X activity promotes *M. tuberculosis* proliferation upon infection.
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